| Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised … MS Hofman, N Lawrentschuk, RJ Francis, C Tang, I Vela, P Thomas, ... The Lancet 395 (10231), 1208-1216, 2020 | 1638 | 2020 |
| Enzalutamide with standard first-line therapy in metastatic prostate cancer ID Davis, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ... New England Journal of Medicine 381 (2), 121-131, 2019 | 1417 | 2019 |
| [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study MS Hofman, J Violet, RJ Hicks, J Ferdinandus, SP Thang, T Akhurst, ... The Lancet Oncology 19 (6), 825-833, 2018 | 1051 | 2018 |
| Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study JW Yaxley, GD Coughlin, SK Chambers, S Occhipinti, H Samaratunga, ... The Lancet 388 (10049), 1057-1066, 2016 | 777 | 2016 |
| [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ... The Lancet 397 (10276), 797-804, 2021 | 749 | 2021 |
| Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study GD Coughlin, JW Yaxley, SK Chambers, S Occhipinti, H Samaratunga, ... The Lancet Oncology 19 (8), 1051-1060, 2018 | 496 | 2018 |
| Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer W Xie, MM Regan, M Buyse, S Halabi, PW Kantoff, O Sartor, H Soule, ... Journal of Clinical Oncology 35 (27), 3097-3104, 2017 | 432 | 2017 |
| Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes J Violet, P Jackson, J Ferdinandus, S Sandhu, T Akhurst, A Iravani, ... Journal of Nuclear Medicine 60 (4), 517-523, 2019 | 409 | 2019 |
| Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial A Kneebone, C Fraser-Browne, GM Duchesne, R Fisher, M Frydenberg, ... The Lancet Oncology 21 (10), 1331-1340, 2020 | 297 | 2020 |
| Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration … J Violet, S Sandhu, A Iravani, J Ferdinandus, SP Thang, G Kong, ... Journal of Nuclear Medicine 61 (6), 857-865, 2020 | 277 | 2020 |
| Use of individual fraction size data from 3756 patients to directly determine the α/β ratio of prostate cancer SG Williams, JMG Taylor, N Liu, Y Tra, GM Duchesne, LL Kestin, ... International Journal of Radiation Oncology* Biology* Physics 68 (1), 24-33, 2007 | 191 | 2007 |
| Prostate cancer–specific PET radiotracers: A review on the clinical utility in recurrent disease JD Evans, KR Jethwa, P Ost, S Williams, ED Kwon, VJ Lowe, BJ Davis Practical radiation oncology 8 (1), 28-39, 2018 | 188 | 2018 |
| Urethral stricture following high dose rate brachytherapy for prostate cancer L Sullivan, SG Williams, KH Tai, F Foroudi, L Cleeve, GM Duchesne Radiotherapy and Oncology 91 (2), 232-236, 2009 | 178 | 2009 |
| Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics C Proust-Lima, JMG Taylor, S Sécher, H Sandler, L Kestin, T Pickles, ... International Journal of Radiation Oncology* Biology* Physics 79 (1), 195-201, 2011 | 173 | 2011 |
| Health-related quality of life, psychological distress, and sexual changes following prostate cancer: a comparison of gay and bisexual men with heterosexual men JM Ussher, J Perz, A Kellett, S Chambers, D Latini, ID Davis, D Rose, ... The journal of sexual medicine 13 (3), 425-434, 2016 | 169 | 2016 |
| Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for 177Lu … SP Thang, J Violet, S Sandhu, A Iravani, T Akhurst, G Kong, AR Kumar, ... European urology oncology 2 (6), 670-676, 2019 | 168 | 2019 |
| Soy and soy isoflavones in prostate cancer: a systematic review and meta‐analysis of randomized controlled trials MD Die, KM Bone, SG Williams, MV Pirotta BJU international 113 (5b), E119-E130, 2014 | 168 | 2014 |
| Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG oncology RTOG 0521 trial SA Rosenthal, C Hu, O Sartor, LG Gomella, MB Amin, J Purdy, ... Journal of Clinical Oncology 37 (14), 1159, 2019 | 161 | 2019 |
| Online adaptive radiotherapy for muscle-invasive bladder cancer: results of a pilot study F Foroudi, J Wong, T Kron, A Rolfo, A Haworth, P Roxby, J Thomas, ... International Journal of Radiation Oncology* Biology* Physics 81 (3), 765-771, 2011 | 161 | 2011 |
| Real‐time individual predictions of prostate cancer recurrence using joint models JMG Taylor, Y Park, DP Ankerst, C Proust‐Lima, S Williams, L Kestin, ... Biometrics 69 (1), 206-213, 2013 | 153 | 2013 |
Shahneen SandhuPeter MacCallum Cancer CentreVerified email at petermac.org
